ClinicalTrials.gg
CompletedNCT00841672Updated Jul 12, 2011Results posted

Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension

A Phase 3 interventional study of Aliskiren/amlodipine 300/10 mg tablet and Amlodipine 10 mg capsule in Moderate to Severe Hypertension, sponsored by Novartis. Completed at 6 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-07-12.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
485
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 228 studies in Hypertension by Novartis — 5 open to participants now, 6 under way, none of them phase 3. Hypertension · Novartis.

Enrollment
80th of 223
485 · median 300
Started
2009
with 16 others
Phase 3
108 of 228
none open now
Registered
160th of 228
by date

Among the 228 studies in Hypertension by Novartis, this one is the 80th largest by enrollment of the 223 interventional ones that give a count, is one of 17 that started in 2009, is one of 108 in phase 3, and was the 160th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 228 studies in Hypertension by Novartis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 228 studies in Hypertension by Novartis, or all of them as a file.
02

Study summary

This study will compare the blood pressure (BP) lowering effect of the combination of aliskiren/amlodipine 300/10 mg versus amlodipine 10 mg monotherapy in patients with moderate to severe hypertension by testing the hypothesis that the combination of aliskiren/amlodipine produces a superior reduction from baseline in mean sitting systolic blood pressure (msSBP) after 8 weeks of treatment.

03

Conditions studied

  • Moderate to Severe Hypertension

Keywords

  • Hypertension
  • systolic blood pressure
  • cardiovascular disease
  • aliskiren
  • amlodipine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients ≥ 18 years of age
  • Patients with a diagnosis of moderate to severe hypertension, defined as msSBP ≥ 160 mmHg and \< 200 mmHg at Visit 2

Exclusion criteria

Exclusion Criteria:

  • Mild to moderate hypertension
  • Pregnant or nursing (lactating) women
  • Women of
  • Previous or current diagnosis of heart failure (NYHA) Class II-IV.
  • Serum potassium ≥ 5.3 mEq/L (mmol/L) at Visit 1.
  • Uncontrolled Type 1 or Type 2 diabetes mellitus
  • to renin inhibitors, calcium channel blockers, or to drugs with Similar chemical structures
  • History of hypertensive encephalopathy or cerebrovascular accident, or history of (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention
  • Patients on a combination of 3 or more antihypertensive medications

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
485 participants (actual)

Study arms

  • Experimental
    Aliskiren/amlodipine 300/10 mg tablet

    Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg.

    Drug: Aliskiren/amlodipine 300/10 mg tablet

  • Active comparator
    Amlodipine 10 mg capsule

    Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg.

    Drug: Amlodipine 10 mg capsule

Interventions

  • DrugAliskiren/amlodipine 300/10 mg tablet

    Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.

  • DrugAmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.

06

What researchers measure

Primary outcomes

  1. Mean Sitting Systolic Blood Pressure (msSBP)

    Change in mean sitting systolic blood pressure (msSBP) from baseline to end of study (Week 8)

    Time frame: Baseline to end of study (Week 8)

Secondary outcomes

  1. Mean Sitting Diastolic Blood Pressure (msDBP)

    Change in mean sitting diastolic blood pressure (msDBP) from baseline to end of study (Week 8)

    Time frame: Baseline to end of study (Week 8)

  2. Systolic Blood Pressure Response

    Percentage of patients achieving a mean sitting systolic blood pressure response (msSBP \< 140 mmHg or a reduction =\> 20 mmHg from the baseline) from baseline to end of study (Week 8)

    Time frame: Baseline to end of study (Week 8)

  3. Diastolic Blood Pressure Response

    Percentage of patients achieving a mean sitting diastolic blood pressure response (msDBP \< 90 mmHg or a reduction ≥ 10 mmHg from the baseline) from baseline to end of study (Week 8)

    Time frame: Baseline to end of study (Week 8)

  4. Blood Pressure Control

    Percentage of patients achieving blood pressure control (msSBP \< 140 mm Hg and msDBP \< 90 mm Hg) at end of study

    Time frame: End of study (Week 8)

07

Results

Posted Jun 27, 2011

Participant flow

Participant flow — Overall Study
MilestoneAliskiren/Amlodipine 300/10 mg TabletAmlodipine 10 mg Capsule
Started244241
Completed224209
Not completed2032
Withdrew: Adverse event716
Withdrew: Abnormal test procedure result(s)01
Withdrew: Subject withdrew consent24
Withdrew: Lost to follow-up11
Withdrew: Administrative problems99
Withdrew: Misrandomized10
Withdrew: Protocol deviation01

Outcome measures

PrimaryMean Sitting Systolic Blood Pressure (msSBP)

Change in mean sitting systolic blood pressure (msSBP) from baseline to end of study (Week 8)

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Mean Sitting Systolic Blood Pressure (msSBP)
mm HgAliskiren/Amlodipine 300/10 mg TabletAmlodipine 10 mg Capsule
Mean Sitting Systolic Blood Pressure (msSBP)-37.72 ± 0.937-30.63 ± 0.941
SecondaryMean Sitting Diastolic Blood Pressure (msDBP)

Change in mean sitting diastolic blood pressure (msDBP) from baseline to end of study (Week 8)

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Mean Sitting Diastolic Blood Pressure (msDBP)
mm HgAliskiren/Amlodipine 300/10 mg TabletAmlodipine 10 mg Capsule
Mean Sitting Diastolic Blood Pressure (msDBP)-16.10 ± 0.557-12.27 ± 0.559
SecondarySystolic Blood Pressure Response

Percentage of patients achieving a mean sitting systolic blood pressure response (msSBP \< 140 mmHg or a reduction =\> 20 mmHg from the baseline) from baseline to end of study (Week 8)

Time frame:
Baseline to end of study (Week 8)
Reported as:
Number · Percentage of participants
Systolic Blood Pressure Response
Percentage of participantsAliskiren/Amlodipine 300/10 mg TabletAmlodipine 10 mg Capsule
Systolic Blood Pressure Response88.879.1
SecondaryDiastolic Blood Pressure Response

Percentage of patients achieving a mean sitting diastolic blood pressure response (msDBP \< 90 mmHg or a reduction ≥ 10 mmHg from the baseline) from baseline to end of study (Week 8)

Time frame:
Baseline to end of study (Week 8)
Reported as:
Number · Percentage of participants
Diastolic Blood Pressure Response
Percentage of participantsAliskiren/Amlodipine 300/10 mg TabletAmlodipine 10 mg Capsule
Diastolic Blood Pressure Response92.786.5
SecondaryBlood Pressure Control

Percentage of patients achieving blood pressure control (msSBP \< 140 mm Hg and msDBP \< 90 mm Hg) at end of study

Time frame:
End of study (Week 8)
Reported as:
Number · Percentage of participants
Blood Pressure Control
Percentage of participantsAliskiren/Amlodipine 300/10 mg TabletAmlodipine 10 mg Capsule
Blood Pressure Control67.049.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aliskiren/Amlodipine 300/10 mg Tablet—0/243 (0%)41/243 (16.9%)
Amlodipine 10 mg Capsule—3/241 (1.2%)56/241 (23.2%)
Most frequent serious events
Most frequent serious events
EventAliskiren/Amlodipine 300/10 mg TabletAmlodipine 10 mg Capsule
AnaemiaBlood and lymphatic system disorders0/2431/241
Myocardial infarctionCardiac disorders0/2431/241
Cerebral infarctionNervous system disorders0/2431/241
AdenomyosisReproductive system and breast disorders0/2431/241
Dysfunctional uterine bleedingReproductive system and breast disorders0/2431/241
Most frequent other events
Most frequent other events
EventAliskiren/Amlodipine 300/10 mg TabletAmlodipine 10 mg Capsule
Oedema peripheralGeneral disorders35/24344/241
HeadacheNervous system disorders8/24313/241

Baseline characteristics

Age Continuous
Age Continuous(years)Aliskiren/Amlodipine 300/10 mg TabletAmlodipine 10 mg CapsuleTotal
Mean59 ± 10.3859 ± 10.8259 ± 10.60
Sex: Female, Male
Sex: Female, Male(Participants)Aliskiren/Amlodipine 300/10 mg TabletAmlodipine 10 mg CapsuleTotal
Female136139275
Male108102210
08

Study locations

6 sites
  • Investigative Site
    Berlin, Germany
  • Investigative Site
    Manilla, Philippines
  • Investigative Site
    Bucharest, Romania
  • Investigative Site
    Moscow, Russian Federation
  • Investigative Site
    Singapore, Singapore
  • Investigative Site
    Madrid, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2009
First posted
Feb 11, 2009
Start
Jan 2009
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Jun 27, 2011
Last update
Jul 12, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00841672
Lead sponsor
Novartis
First posted
Feb 11, 2009
Start date
Jan 2009
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Jun 27, 2011
Last update
Jul 12, 2011

Study contacts

Novartis
study director · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion